PHILADELPHIA, PA — Imvax, Inc. is set to highlight its innovative research on glioblastoma treatment at the 2024 Society for NeuroOncology (SNO) Annual Meeting in Houston, Texas, from November 21-24. The Philadelphia-based company’s presentations will focus on IGV-001, a novel autologous cell immunotherapy designed for patients newly diagnosed with glioblastoma.
During the conference, Imvax will unveil blinded safety data from its ongoing Phase 2b clinical trial of IGV-001. This randomized, multicenter, double-blind, placebo-controlled study aims to evaluate the safety and efficacy of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM), with top-line results anticipated by mid-2025.
The presentations include a detailed oral session scheduled for November 22, from 7:25 p.m. to 7:35 p.m. CST, by Dr. Brad Elder. This session will cover early safety data from the Phase 2b study. Additionally, two poster presentations will be held on November 21-22, featuring follow-up data from a Phase 1b study and preclinical results on IGV-001’s effectiveness both as a standalone therapy and in conjunction with checkpoint inhibitors.
On November 22, from 12:45 p.m. to 1:45 p.m. CST, Imvax will conduct a symposium led by Raul Perez-Olle, M.D., Ph.D., alongside esteemed colleagues Dr. Brad Zacharia and Dr. Brad Elder. This session, titled “Development of IGV-001 for the treatment of newly diagnosed glioblastoma,” will delve into Imvax’s proprietary Goldspire® platform and its application in advancing glioblastoma treatment.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.